MedTrace Logo

Impact of OptiCreatine on Plasma Creatine and Gastrointestinal Effects in Males and Females

NCT07225335 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2026-03-12

No results posted yet for this study

Summary

The study aims to evaluate the novel OptiCreatine formulation, which combines creatine with other bioactive compounds purported to enhance absorption and reduce gastrointestinal (GI) discomfort. Using a randomized, double-blind, crossover design, the study will compare the acute and chronic effects of OptiCreatine versus Creatine monohydrate in healthy, recreationally active adults. Participants will be asked to orally consume both the OptiCreatine and the creatine monohydrate. Primary outcomes include plasma creatine concentrations, gastrointestinal symptomatology, and fluid distribution measured through bioelectrical impedance spectroscopy.

Conditions

  • Creatine Absorption in Healthy Adults

Interventions

DIETARY_SUPPLEMENT

OptiCreatine

OptiCreatine is a formulation, which combines creatine with other bioactive compounds purported to enhance absorption.

DIETARY_SUPPLEMENT

Creatine Monohydrate

Creatine monohydrate (Creapure®)

Sponsors & Collaborators

  • University of North Carolina

    collaborator OTHER

  • TSI Group LTD

    lead INDUSTRY

Principal Investigators

  • John A Rathmacher, Ph.D. · TSI Group LTD

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-05
Primary Completion
2025-12-19
Completion
2025-12-19

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07225335 on ClinicalTrials.gov